Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives

Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives

The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.

Bibliographic Details
Main Authors:	A. E. Russkikh, D. M. Kutuzova, O. V. Lovacheva, A. G. Samoylova, I. A. Vasilyeva
Format:	Article
Language:	Russian
Published:	NEW TERRA Publishing House 2021-01-01
Series:	Tuberkulez i Bolezni Lëgkih
Subjects:	short course treatment regimens treatment of tuberculosis multiple drug resistant tuberculosis bedaquiline moxifloxacin clofazimine delamanid pretomanid linezolid bpal regimen
Online Access:	https://www.tibl-journal.com/jour/article/view/1496

Similar Items

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
by: L. Guglielmetti, et al.
Published: (2021-09-01)

New regimens and new medications in the treatment of tuberculosis: keeping step?
by: Ruzanov D.Y., et al.
Published: (2021-04-01)

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
by: S. E. J. van de Berg, et al.
Published: (2021-07-01)

Pretomanid: Clinical Trials and Prospects to Be Used in Treatment Regimens for Multiple and Extensive Drug Resistant Tuberculosis
by: A. V. Kukurika
Published: (2021-07-01)

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
by: Connie A. Haley, et al.
Published: (2021-01-01)

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01)

Tuberculose à bacilles résistants aux antibiotiques en France : épidémiologie et prise en charge
by: Guglielmetti, Lorenzo
Published: (2018)

Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study
by: Nazir A. Ismail, et al.
Published: (2018-02-01)

Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases
by: Hollis D. Showalter
Published: (2020-09-01)

THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE
by: I. A. Vasilyeva, et al.
Published: (2017-11-01)

Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results
by: P. N. Golubchikov, et al.
Published: (2019-09-01)

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
by: S. Koirala, et al.
Published: (2021-09-01)

Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis
by: Ping Xu, et al.
Published: (2017-07-01)

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
by: Wencong He, et al.
Published: (2021-09-01)

Classifying new anti-tuberculosis drugs: rationale and future perspectives
by: Simon Tiberi, et al.
Published: (2017-03-01)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
by: Myungsun Lee, et al.
Published: (2019-01-01)

Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains
by: Battaglia, S., et al.
Published: (2021)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
by: François Ciza, et al.
Published: (2020-06-01)

Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study
by: Anastasiia Russkikh, et al.
Published: (2021-01-01)

A clinical case of successful combined treatment of a patient with fibrous cavernous pulmonary tuberculosis and extensive drug resistance
by: P. N. Golubchikov, et al.
Published: (2020-07-01)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
by: Andrey Maryandyshev, et al.
Published: (2017-10-01)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
by: Marie Jaspard, et al.
Published: (2017-10-01)

A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
by: Ju Mi Lee, et al.
Published: (2021-01-01)

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
by: Jennifer Furin, et al.
Published: (2016-03-01)

Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations
by: Emily A. Kendall, et al.
Published: (2019-09-01)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
by: Uzma Khan, et al.
Published: (2019-08-01)

EXPERIENCE OF SHORT-COURSE TREATMENT IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: A. A. Toktogonovа, et al.
Published: (2018-06-01)

Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study
by: Abyot Asres, et al.
Published: (2016-11-01)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
by: Arnaud Trébucq, et al.
Published: (2019-12-01)

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?
by: Aleksey G. Naumov, et al.
Published: (2018-11-01)

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis
by: Saeed Khoshnood, et al.
Published: (2021-10-01)

Treatment of Drug-Resistant Tuberculosis: Current Status
by: Rajendra Prasad, et al.
Published: (2021-04-01)

EPIDEMIC SITUATION AND TREATMENT PROSPECTS OF MULTIPLE RESISTANT TUBERCULOSIS IN KANTY-MANSIYSKY AUTONOMOUS REGION
by: E. S. Ershovа, et al.
Published: (2018-05-01)

Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple drug resistance
by: T. I. Morozova, et al.
Published: (2016-02-01)

Effekten och potentiella risker med bedaquiline, delamanid och pretomanid vid behandling av multiresistent tuberkulos
by: Jansson, Alexandra
Published: (2019)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
by: Hu MH, et al.
Published: (2016-12-01)